Ulta Lab Tests

Post COVID-19 Coagulation Panel (Long Covid)

There are no preparation instructions.

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.

Also known as: DDimer Quantitative

D-Dimer, Quantitative

Also known as: Factor I, Fibrinogen, Fibrinogen Activity Clauss

Fibrinogen Activity,

Fibrinogen is a protein produced by the liver. This protein helps stop bleeding by helping blood clots to form. A blood test can be done to tell how much fibrinogen you have in the blood.
*Important Information on Lab Test Processing Times: Ulta Lab Tests is committed to informing you about the processing times for your lab tests processed through a national lab. Please note that the estimated processing time for each test, indicated in business days, is based on data from the past 30 days across the 13 laboratories for each test. These estimates are intended to serve as a guide and are not guarantees. Factors such as laboratory workload, weather conditions, holidays, and the need for additional testing or maintenance can influence actual processing times. We aim to offer estimates to help you plan accordingly. Please understand that these times may vary, and processing times are not guaranteed. Thank you for choosing Ulta Lab Tests for your laboratory needs.

The Post COVID-19 Coagulation Panel (Long Covid) panel contains 2 tests with 2 biomarkers .

Brief Description: The Post COVID-19 Coagulation (Long Covid) Panel is designed to evaluate the coagulation status of individuals who have recovered from COVID-19 but continue to experience long-term effects, commonly referred to as "Long Covid." This condition has been observed to affect multiple systems within the body, including the coagulation system, which is crucial for blood clotting and wound healing processes. By assessing markers such as D-Dimer and Fibrinogen Activity, healthcare professionals can monitor patients' recovery from COVID-19 and manage any ongoing risks related to blood clotting disorders.

Collection Method: Blood Draw

Specimen Type: Whole Blood

Test Preparation: No preparation required

When and Why the Post COVID-19 Coagulation (Long Covid) Panel May Be Ordered

The Post COVID-19 Coagulation (Long Covid) Panel may be ordered for individuals who have a history of COVID-19 infection and are experiencing persistent symptoms associated with Long Covid, such as fatigue, difficulty breathing, or cardiovascular issues. These symptoms may be indicative of underlying coagulation abnormalities. The panel helps to identify these abnormalities, which can contribute to the development of blood clots, thus facilitating timely intervention to prevent more serious complications.

What the Post COVID-19 Coagulation (Long Covid) Panel Checks For

D-Dimer Quantitative

The D-Dimer test measures the levels of D-Dimer in the blood, which is a protein fragment produced when a blood clot dissolves. Elevated levels of D-Dimer can indicate that there is significant clot formation and breakdown in the body, suggesting an increased risk of thrombotic events. This test is particularly important for patients recovering from COVID-19, as the virus has been associated with an increased risk of blood clots.

Fibrinogen Activity, Clauss

Fibrinogen is a protein essential for blood clot formation. The Fibrinogen Activity test measures the activity level of fibrinogen in the blood using the Clauss method. Changes in fibrinogen levels can indicate alterations in the body's ability to form clots. In the context of Long Covid, abnormal fibrinogen activity can reflect ongoing inflammation or an increased risk of clotting disorders.

Conditions or Diseases Detected by the Post COVID-19 Coagulation (Long Covid) Panel

Thrombosis

Thrombosis refers to the formation of blood clots within blood vessels, which can lead to blockages affecting various organs. Elevated D-Dimer levels in the Post COVID-19 Coagulation Panel can indicate an increased risk of thrombosis, necessitating further investigation and possibly anticoagulant therapy to prevent clot formation.

Coagulopathy

Coagulopathy is a condition where the blood's ability to clot is impaired, leading to an increased risk of bleeding or, conversely, clotting. Abnormal results from both D-Dimer and Fibrinogen Activity tests can suggest the presence of a coagulopathy related to Long Covid, requiring management to correct the underlying imbalance.

Using the Results in Treatment and Monitoring

Thrombosis

For patients showing signs of an increased thrombotic risk through elevated D-Dimer levels, healthcare professionals may recommend anticoagulant medications to reduce the risk of clot formation. Regular monitoring of coagulation markers, alongside clinical assessment, guides the adjustment of therapy and prevention of complications.

Coagulopathy

In cases where the panel indicates a coagulopathy, treatment focuses on addressing the underlying cause and may involve the use of medications to either promote clotting or prevent excessive clot formation, depending on the patient's specific condition. Continuous monitoring of coagulation markers helps in managing the coagulopathy effectively and adjusting treatment as the patient recovers from Long Covid.

The Post COVID-19 Coagulation (Long Covid) Panel plays a vital role in the management and monitoring of patients experiencing long-term effects following a COVID-19 infection. By assessing key coagulation markers, this panel aids in the early detection and treatment of conditions such as thrombosis and coagulopathy, which are known complications of Long Covid. The results from this panel enable healthcare professionals to implement targeted interventions, improving patient outcomes and reducing the risk of severe complications associated with abnormal coagulation states.

We advise having your results reviewed by a licensed medical healthcare professional for proper interpretation of your results.

Customer Reviews